Market Place
Sourcing Support
RespireRx Gets DoD Award For CX1739 Spinal Cord Injury Bladder Study
29 May 2024 //
GLOBENEWSWIRE
RespireRx Pharma Reports Pub.of Preclinical Research Results Ability of CX1739
20 Mar 2024 //
GLOBENEWSWIRE
RespireRx Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine
13 Feb 2024 //
GLOBENEWSWIRE
RespireRx Announces the Appointment of Dr. Dariusz Naziek to Board of Directors
22 Jan 2024 //
GLOBENEWSWIRE
RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures
11 Dec 2023 //
GLOBENEWSWIRE
ResolutionRx Ltd Enters into Agreement for Dronabinol Manufacturing
12 Oct 2023 //
GLOBENEWSWIRE
RespireRx Pharmaceuticals and ResolutionRx Ltd Enter into Bilateral Agreements
09 Aug 2023 //
GLOBENEWSWIRE
ResolutionRx a Subsidiary of RespireRx , Enters into Letter of with Cantheon
24 May 2023 //
GLOBENEWSWIRE
RespireRx stablishes Research Collaboration With University College London
05 Apr 2023 //
GLOBENEWSWIRE
RespireRx Discloses Analogs of its GABAA Receptor Potentiator, KRM-II-81
03 Apr 2023 //
GLOBENEWSWIRE
RespireRx Announces the Appointment Joseph Siegelbaum in Board of Directors
28 Mar 2023 //
GLOBENEWSWIRE
ResolutionRx & RespireRx Announce ResolutionRx Entry into Services Agreement
01 Mar 2023 //
GLOBENEWSWIRE
ResolutionRx Enters into LOI and Term Sheet with Radium Capital
01 Feb 2023 //
GLOBENEWSWIRE
RespireRx Announces the Amendment to Agreement with the University of Illinois
23 Jan 2023 //
GLOBENEWSWIRE
US-based RespireRx Pharmaceuticals establishes Australian subsidiary
16 Jan 2023 //
BIOSPECTRUM ASIA
RespireRx Establishes ResolutionRx in Australia to Develop Cannabinoid Platform
12 Jan 2023 //
GLOBENEWSWIRE
RespireRx Enters a Collaboration National Institute for Neurological Disorders
05 Dec 2022 //
GLOBENEWSWIRE
RespireRx Announces Entry into Letter of Intent with Australian HD CRO
17 Nov 2022 //
GLOBENEWSWIRE
RespireRx Pharmaceuticals Inc. Announces that Jeff Margolis, the Company’s CFO
10 Nov 2022 //
GLOBENEWSWIRE
RespireRx Pharmaceuticals Announces that Dr. Arnold Lippa Is an Invited Speaker
07 Nov 2022 //
GLOBENEWSWIRE
RespireRx Announces that Sleep Review has discussed Dronabinol OSA Program
08 Aug 2022 //
GLOBENEWSWIRE
RespireRx Pharma Announces Recent RespireRx Presentation at 2022 GRI
17 May 2022 //
GLOBENEWSWIRE
RespireRx Announces Publication of Review Article for GABAkine Neuromodulators
16 May 2022 //
GLOBENEWSWIRE
RespireRx Pharma Filees Patent Claiming Novel Lipid Based Formulations
23 Mar 2022 //
GLOBENEWSWIRE
RespireRx Pharma says Discovery of New GABAkine Neuromodulator
16 Mar 2022 //
GLOBENEWSWIRE
RespireRx to Publish Manuscript Describing Its Neuromodulator
24 Jan 2022 //
GLOBENEWSWIRE
RespireRx Pharmac to Present at Upcoming Virtual Life Sciences Conference
14 Dec 2021 //
GLOBENEWSWIRE
RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results
29 Nov 2021 //
GLOBENEWSWIRE
RespireRx Announces New Data on the use of AMPAkines for Spinal Cord Injury
12 May 2021 //
GLOBENEWSWIRE
RespireRx Pharmaceuticals Inc. Provides Update on Its Development Programs
22 Apr 2021 //
GLOBENEWSWIRE
RespireRx Announces Preclinical Results of Ampakines in Treatment of SCI
06 Oct 2020 //
GLOBENEWSWIRE
